Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951201 | 1.00 | ENPP2 (0.33) | ENPP2P2RX7TNFRIPK1ADRA2A | |
| SCHEMBL29956143 | 0.82 | TNF (0.39) | ENPP2TNFRIPK1 | |
| SCHEMBL5422266 | 0.78 | ALDH1A1 (0.42) | ENPP2CLCN2CYP3A4 | |
| SCHEMBL29955010 | 0.78 | TNF (0.36) | ENPP2TNFRIPK1CYP3A4 | |
| SCHEMBL15609444 | 0.78 | ACHE (0.32) | ACHE | |
| SCHEMBL29952822 | 0.78 | ALDH1A1 (0.42) | ENPP2CLCN2CYP3A4 | |
| SCHEMBL28136581 | 0.78 | ACHE (0.32) | ACHE | |
| SCHEMBL21543102 | 0.77 | ALDH1A1 (0.37) | ACHE | |
| SCHEMBL29955796 | 0.77 | MAPK1 (0.39) | ENPP2TNFRIPK1CYP3A4 | |
| SCHEMBL29491113 | 0.77 | ALDH1A1 (0.37) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ENPP2 147/4885P2RX7 491/4885TNF 4037/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ENPP2 1794/4885P2RX7 4433/4885TNF 4497/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ENPP2 147/4885P2RX7 491/4885TNF 4037/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | ENPP2 854/4885P2RX7 4345/4885TNF 189/4885 |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | ENPP2 36/4885P2RX7 889/4885TNF 2672/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | ENPP2 557/4885P2RX7 4249/4885TNF 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.